The purpose of this chapter is to provide a detailed review of those aspects of HCL that primarily concern the clinician. We have limited detailed numerical analysis of previous work to those studies giving clinical accounts of several patients [5, 16, 21, 28, 32, 40, 43, 111, 112, 149, 167, 175, 189, 202, 226, 269, 298, 322, 337, 340, 342, 373, 395]. Isolated case reports mainly concerned with a single particular aspect of the disease have been excluded and, where sequential reports have appeared from a centre, an attempt has been made to avoid including the same patient more than once. The present chapter thus reviews a total of some 500 patients, but, since the published data are often incomplete, parts of the clinical analysis are based on rather fewer patients. The personal comments included in this section are drawn from our clinical experience of 30 cases.
KeywordsSplenic Infarction Mean Cell Volume Haematological Improvement Antituberculous Therapy Serum Lysozyme
Unable to display preview. Download preview PDF.